[144] CorMedix Inc. SEC Filing

Rhea-AI Filing Summary

CorMedix Inc. filed a Form 144 reporting a proposed sale of 53,997 common shares through Merrill Lynch on 09/09/2025. The filing lists an aggregate market value of $728,959.00 and indicates 74,648,992 shares outstanding for the issuer. The shares were acquired the same day (09/09/2025) under a stock plan activity from the issuer, with payment recorded as n/a. No securities were reported sold by the filer in the prior three months. The notice includes the standard statement that the seller does not possess undisclosed material adverse information and warns that false statements are criminally punishable.

Positive

• Transparent disclosure of the proposed sale including share count and aggregate market value
• Shares originated from a stock plan, indicating issuance-based transactions rather than third-party transfers
• No reported sales by the filer in the prior three months, per the filing

Negative

• Insider selling of common stock (53,997 shares) could be viewed negatively by some investors
• Key filer details (CIK, contact name, and contact information) are not provided in the visible content

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice for a same-day stock plan sale of 53,997 shares valued at $728,959; disclosure is timely and standard.

The Form 144 shows a proposed sale executed through a broker with the securities acquired under a stock plan on the same date as the planned sale. This pattern is consistent with issuances followed promptly by Rule 144 notices when holders intend to sell. The filing provides specific quantities, market value and outstanding shares, which allows investors to quantify the transaction size relative to the company’s share count. There are no reported prior sales in the past three months by this filer, and no additional pricing or lock-up details are provided.

Corporate Governance Specialist

TL;DR: Disclosure aligns with compliance expectations; no governance flags disclosed in this form.

The document contains the standard attestation about material non-public information and a signature notice, which are required for Rule 144 filings. The origin of the shares is noted as issuer stock plan activity, which suggests the transaction stems from compensation or awards rather than an unexpected insider disposition. The form does not include any additional governance disclosures, special restrictions, or aggregation details beyond what Rule 144 requires.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006	53997	728959.00	74648992	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2025	Stock Plan Activity	Issuer			53997	09/09/2025	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does CorMedix (CRMD) Form 144 report?

The filing reports a proposed sale of 53,997 common shares through Merrill Lynch on 09/09/2025, with aggregate market value of $728,959.00.

How were the shares acquired that are being sold under the Form 144?

The shares were acquired on 09/09/2025 via stock plan activity from the issuer.

Does the Form 144 show any sales by this filer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Through which broker will the CRMD shares be sold?

The broker listed is Merrill Lynch at the Washington, DC address shown on the form.

What does the filing say about material non-public information?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.